Generic Biologics Provide Significant Growth Opportunity, Barr Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr plans to limit its biotech projects to four until a regulatory pathway for follow-on biologics is established, CEO Downey says. The generic industry is arguing for “common sense” rules, he asserts.